research use only

D-Aspartic acid NMDAR modulator

Name: D-Aspartic acid
Brand: Selleck Chemicals
SKU: S5129
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S5129

D-Aspartic acid (D-Asp, Aminosuccinic acid, asparagic acid, asparaginic acid) is an endogenous amino acid occurring in several tissues and cells of both invertebrates and vertebrates. It can regulate testosterone synthesis and may act on a stimulatory receptor (NMDA).

Chemical Structure

Molecular Weight: 133.10

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S512901 5%TFA]6.02 mg/mL]false]DMSO]0.01 mg/mL]false]Water]Insoluble]false Purity: 98%

Related Targets	Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel GluR MAO Beta Amyloid P2 Receptor Trk receptor Serotonin Transporter Notch Cannabinoid Receptor P-gp CaMK Opioid Receptor BACE Sigma Receptor FAAH Neurokinin Receptor OX Receptor CGRP Receptor BChE Adenosine Deaminase CCK receptor MT Receptor
Related Products	(+)-Dizocilpine (MK 801) Maleate (-)-Dizocilpine (MK 801) Maleate NMDA (N-Methyl-D-aspartic acid) Ifenprodil Tartrate Memantine HCl Spermidine trihydrochloride Kynurenic acid Mephenesin

Chemical Information, Storage & Stability

Molecular Weight	133.10	Formula	C₄H₇NO₄	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1783-96-6	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Asp, Aminosuccinic acid, asparagic acid, asparaginic acid			Smiles	C(C(C(=O)O)N)C(=O)O

Solubility

In vitro
Batch:

5%TFA : 6.02 mg/mL

DMSO : 0.01 mg/mL ( (0.07 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro	D-aspartate (D-Asp) is an endogenous amino acid present in vertebrate tissues, with particularly high levels in the testis. In vitro studies have demonstrated that D-Asp up-regulates testosterone production in Leydig cells by enhancing expression of the steroidogenic acute regulatory protein. Besides testosterone release, D-Asp induced E2 synthesis through aromatase activation^[1].
In vivo	In vivo studies indicate that D-Asp indirectly stimulates spermatogenesis through the hypothalamic-pituitary-gonadal axis. The oral and/or intraperitoneal D-Asp administration to adult rats induced an increase of serum progesterone and LH as well as an increase of testis/serum testosterone levels, whereas 17β-estradiol (E2) levels did no change^[1]. D-aspartic acid has significant analgesic activity^[2].
References	https://pubmed.ncbi.nlm.nih.gov/26189884/ https://pubmed.ncbi.nlm.nih.gov/7675849/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05847179	Not yet recruiting	Werner Syndrome	PRG Science & Technology Co. Ltd.	January 1 2025	Phase 2
NCT05777512	Recruiting	Bronchopulmonary Dysplasia	Boston Children''s Hospital\|Beth Israel Deaconess Medical Center	October 2024	Not Applicable
NCT06405555	Not yet recruiting	Heart Failure With Reduced Ejection Fraction\|Hypotension\|LV Dysfunction	Ottawa Heart Institute Research Corporation	August 1 2024	Phase 2\|Phase 3
NCT05638568	Not yet recruiting	Surfactant Deficiency Syndrome Neonatal\|Respiratory Distress Syndrome Newborn\|Bronchopulmonary Dysplasia	Rigshospitalet Denmark\|Odense University Hospital\|Aalborg University Hospital\|Aarhus University Hospital\|Holbaek Sygehus	July 1 2024	Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):